Fibronostics to Present LIVERFASt™ Clinical Data at ADA 2026
Fibronostics will be participating in the upcoming American Diabetes Association (ADA) 2026 Scientific Sessions, taking place from June 5–8, 2026, in New Orleans, Louisiana.
At ADA 2026, Fibronostics will present new clinical findings on LIVERFASt™ and its performance in identifying advanced fibrosis in patients with MASLD, including patients with type 2 diabetes (T2D).
The poster highlights how LIVERFASt™, in sequential combination with vibration-controlled transient elastography (VCTE), supports clearer identification of ≥F3 fibrosis compared with traditional assessment approaches such as FIB-4.
Fibronostics to Present LIVERFASt Data at DDW 2026
Fibronostics is pleased to share that Dr. Mona Munteanu, Chief Scientific Officer at Fibronostics, will be presenting new data on LIVERFASt™ at Digestive Disease Week (DDW) 2026, taking place from May 2–5, 2026 in Chicago.
The presentation will be part of the session:
“Noninvasive Tools for MASLD/MASH: Real-World Performance, Pitfalls, and Clinical Integration.”
Presentation Details
Title: Correlations between LIVERFASt, a blood-based non-invasive test, and MRI elastography (MRE) for the assessment of fibrosis and the intracellular fat fraction (ICFF) for the assessment of steatosis in patients with MASLD
Session Type: Abstract Lecture
Date & Time: May 5, 2026 | 8:00–9:30 AM (CDT)
Location: McCormick Place Convention Center, West Building
Advancing Non-Invasive Assessment in MASLD
The study explores how LIVERFASt correlates with established imaging modalities, including MRI elastography (MRE) and intracellular fat fraction (ICFF), in the assessment of fibrosis and steatosis in patients with MASLD.
Understanding the alignment between blood-based diagnostics and imaging approaches is an important step toward:
- Strengthening clinical confidence in non-invasive tools
- Supporting more integrated diagnostic pathways
- Improving how liver disease is assessed in real-world settings
Join Us at DDW 2026
Fibronostics looks forward to engaging with clinicians, researchers, and partners at DDW 2026 as part of the ongoing effort to advance non-invasive liver diagnostics.